Issuance of the Document on Supporting the High-Quality Development of the Biomedical Industry in Shijiazhuang
2023-07-21 00:00
Original Title: Notice Issued by the General Office of the People’s Government of Hebei Province on Several Measures to Support the High-Quality Development of the Biopharmaceutical Industry in Shijiazhuang
To thoroughly implement the important instructions given by General Secretary Xi Jinping during his inspection tour of Hebei, support Shijiazhuang in accelerating the development of a hub for innovation in the biopharmaceutical sector, and promote the high-quality development of the province’s biopharmaceutical industry, the following measures are hereby formulated.
I. Strengthening R&D and Innovation in the Biopharmaceutical Sector
(1) Support Clinical Research and Application. Support provincial-level medical and health institutions in establishing coordination mechanisms with Shijiazhuang’s biopharmaceutical enterprises and R&D institutions to conduct clinical application research through a “challenge-based” approach. (Responsible Units: Provincial Health Commission, Provincial Drug Administration)
(2) Support the Establishment of a Beijing-Tianjin-Hebei Medical Collaborative Innovation Community. Actively coordinate with the National Health Commission, the Ministry of Science and Technology, and other relevant ministries and commissions to integrate medical innovation resources across Beijing, Tianjin, and Hebei. Support Shijiazhuang in establishing a biopharmaceutical intellectual property operation center and a technology transfer center to create conditions for the transfer and commercialization of technologies from biopharmaceutical, medical device, and healthcare enterprises in Beijing and Tianjin. This will facilitate policy coordination, resource sharing, mutual recognition of qualifications, data interoperability, and market openness.(Responsible Units: Provincial Health Commission, Provincial Market Regulation Bureau, Provincial Drug Administration, Provincial Department of Science and Technology, Provincial Development and Reform Commission)
(3) Support the assumption of national drug and medical device review and inspection functions. Actively coordinate with the National Medical Products Administration (NMPA) to secure the establishment of the NMPA Special Drug Inspection Center and the Hebei Service Station of the NMPA Medical Device Innovation Center in Shijiazhuang, thereby promoting technology transfer, industrial clustering, and innovative development.Support the establishment of the National Medical Products Administration’s Beijing-Tianjin-Hebei Sub-Center for Drug Review and Inspection and the Beijing-Tianjin-Hebei Sub-Center for Medical Device Technical Review and Inspection in Shijiazhuang. (Responsible Unit: Provincial Drug Administration)
(4) Support the construction of the Beijing-Tianjin-Hebei Center for Evidence-Based Traditional Chinese Medicine. Actively coordinate with the National Administration of Traditional Chinese Medicine to establish the Beijing-Tianjin-Hebei Center for Evidence-Based Traditional Chinese Medicine in Shijiazhuang, leveraging key local enterprises. Proactively explore new models for standard-setting, quality traceability, and system management to build renowned brands in traditional Chinese medicine. (Responsible Units: Provincial Health Commission, Provincial Administration of Traditional Chinese Medicine, Provincial Market Regulation Bureau)
(5) Support the establishment of a provincial medical translation center. Integrate medical resources within the province to establish the Hebei Provincial Medical Translation Center in Shijiazhuang, covering areas such as animal experiments, basic medical research, and preclinical safety and efficacy evaluations, thereby accelerating the pace of new drug clinical trials at multiple levels. (Responsible units: Provincial Health Commission, Provincial Drug Administration)
(6) Establish a collaborative ethics review mechanism. Establish a clinical research ethics review alliance and explore the creation of a mutual recognition system for ethics review results across multiple centers to effectively reduce redundant ethics reviews in clinical trials and shorten the R&D cycle for innovative products. (Responsible Units: Provincial Health Commission, Provincial Drug Administration)
II. Promoting the Development of Biopharmaceutical Projects
(7) Strengthen Support for Collaboration with Central State-Owned Enterprises. Seek support from the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) to actively engage with central state-owned enterprises in the biopharmaceutical sector. Support Shijiazhuang in undertaking the relocation of non-capital functions from Beijing, and strive to attract more second- and third-tier subsidiaries or innovative business divisions of central state-owned enterprises in the biopharmaceutical sector to establish operations in Shijiazhuang. (Responsible Unit: Provincial SASAC)
(8) Optimize market access management for the biopharmaceutical sector. Biopharmaceutical enterprises that meet ecological and environmental regulatory requirements shall be included in the white list for ecological and environmental supervision, ensuring they are exempt from production halts or output restrictions during periods of severe air pollution or summer ozone control measures.Implement coordinated advancement and overlapping review and approval of environmental impact assessments (EIAs) for both industrial park master plans and projects entering the parks. For construction projects that meet the requirements of the industrial park’s master plan EIA, streamline analyses of policy and planning compliance, as well as arguments regarding the environmental rationality and feasibility of site selection, and share relevant evaluation content regarding the park’s infrastructure. Support provincial key biopharmaceutical projects in accessing green approval channels; where local pollutant emission quotas are insufficient, prioritize allocation through cross-district transfers. (Responsible Unit: Provincial Department of Ecology and Environment)
(9) Support the acceleration of drug and medical device registration. Establish an early intervention mechanism for key products under development by biopharmaceutical enterprises, such as innovative drugs and medical devices, strengthen communication with the National Medical Products Administration, and provide professional guidance. Facilitate registration and production licensing for products such as novel antibody drugs, vaccines for major infectious diseases, and novel vaccine adjuvants to accelerate the registration and approval process.A fast-track review and approval channel will be established for Class II innovative medical devices. For eligible medical device products, processing times will be shortened, with separate queues established to prioritize testing, registration inspections, and review and approval. For Class II medical devices transferred from other provinces, application materials will be streamlined to enhance review and approval efficiency. (Responsible Unit: Provincial Drug Administration)
III. Strengthen the Application of Innovative Products
(10) Support the application of novel formulations. Actively coordinate with the National Health Commission and the National Medical Products Administration to support eligible medical institutions in conducting research and translation of new technologies—such as immunotherapy, genetic engineering, tissue engineering, and stem cell therapies—in accordance with regulations. Support pilot initiatives in the diagnosis and treatment of major infectious diseases and severe, intractable conditions. In cases where patients suffer from severe or life-threatening illnesses, expand the compassionate use of investigational drugs in the clinical trial phase in accordance with laws and regulations.(Responsible Units: Provincial Health Commission, Provincial Drug Administration)
(11) Strengthen support for the application of innovative products. Support the inclusion of drugs from biopharmaceutical enterprises that have been listed in the National Essential Medicines List or secured through national medical insurance negotiations as essential medicines in medical institutions at all levels within the province. Establish a direct communication mechanism among “health authorities—medical insurance—drug regulatory authorities—hospitals—enterprises” to guide high-quality innovative products into provincial medical institutions. (Responsible Units: Provincial Health Commission, Provincial Medical Security Bureau, Provincial Drug Regulatory Bureau)
IV. Expanding the Opening-up of the Biopharmaceutical Sector
(12) Promote customs clearance facilitation. Establish a “whitelist” for biopharmaceutical enterprises and research institutions in Shijiazhuang, as well as a positive list for cross-border research materials, and explore simplifying the pre-approval procedures for relevant items of entities on these lists. For special items such as biopharmaceutical raw materials, blood products, and imported reagents and consumables, adopt multiple inspection methods to accelerate customs clearance. (Responsible entity: Shijiazhuang Customs)
(13) Support the hosting of biopharmaceutical exhibitions. Actively coordinate with the National Development and Reform Commission and the National Health Commission to secure the hosting of national-level industry summits in Shijiazhuang, such as the National Bio-Industry Conference and the National Vaccine and Health Conference, and strive to designate Shijiazhuang as a permanent host city. (Responsible Units: Provincial Development and Reform Commission, Provincial Health Commission)
V. Mobilizing Fiscal and Financial Resources
(14) Support the role of biopharmaceutical industry funds. Encourage provincial government investment guidance funds—such as the Provincial Industrial Investment Guidance Fund, the Jicai Industrial Guidance Equity Investment Fund, and the Provincial Science and Technology Investment Guidance Fund—to collaborate with Shijiazhuang’s leading industrial development funds to establish biopharmaceutical industry sub-funds. Through market-oriented operations, these funds will attract banks, insurance companies, trust companies, investment funds, asset management companies, and other social capital to invest in Shijiazhuang’s biopharmaceutical industry.(Responsible Units: Provincial Development and Reform Commission, Provincial Department of Finance, Provincial Department of Science and Technology, Provincial Bureau of Local Financial Supervision)
(15) Support the Introduction of Investment Entities. Establish a mechanism for joint participation and shared benefits. Encourage national policy-based banks and commercial banks to provide financial support to Shijiazhuang, thereby facilitating rapid progress in infrastructure development and key project construction within the biopharmaceutical park. Encourage provincial and municipal state-owned enterprises, as well as financially strong private enterprises, to actively participate in the construction of infrastructure and key projects in Shijiazhuang’s biopharmaceutical park in accordance with market principles, thereby optimizing the park’s development environment.(Responsible Units: Provincial Bureau of Local Financial Supervision, Provincial State-owned Assets Supervision and Administration Commission)
(16) Launch financial reform pilot programs. Drawing on the experience of science and technology innovation financial reform pilot zones in areas such as Beijing’s Zhongguancun, explore the implementation of science and technology innovation financial business pilots in Shijiazhuang that are suited to local conditions; encourage biopharmaceutical enterprises to raise capital through public listings; and stimulate financial vitality through diverse methods and channels to empower high-quality industrial development. (Responsible Units: Provincial Bureau of Local Financial Supervision, Hebei Securities Regulatory Bureau)
VI. Building a Hub for Biopharmaceutical Talent
(17) Strengthen the recruitment and cultivation of high-level talent and teams in the biopharmaceutical sector. Encourage and support Shijiazhuang City in providing rewards to the principal contributors who have received the First or Second Prize (top three recipients) of the National Science and Technology Award or the First Prize (first recipient) of the Provincial Science and Technology Award. Encourage Shijiazhuang City to prioritize both attracting and cultivating talent, and provide rewards for newly recruited national-level high-level talent. (Responsible Units: Provincial Department of Human Resources and Social Security, Provincial Department of Science and Technology)
(18) Support the development of biopharmaceutical talent centers and innovation hubs.Coordinate with Hebei University of Technology to establish a biomedical research institute in Shijiazhuang; support the development of existing national-level innovation platforms in the biomedical field within Shijiazhuang; and support key enterprises in collaborating with the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences to jointly build provincial-level innovation platforms such as the High-Level Technological Innovation Center for Synthetic Biology. This initiative aims to gather a group of leading scientific and technological talents and innovation teams who master key core technologies and can lead future development, attract outstanding university graduates and young talents, and establish Shijiazhuang as a talent hub and innovation hub within the Beijing-Tianjin-Hebei regional center city.(Responsible Units: Provincial Department of Education, Provincial Department of Science and Technology)
Provide ongoing support for Shijiazhuang’s applications for relevant national pilot and demonstration programs, and assist in coordinating the supply of production factors such as water, electricity, gas, and heat. Encourage Shijiazhuang, within the scope permitted by laws and regulations, to independently formulate and implement more pioneering, breakthrough, catalytic, and leading policy measures focused on the high-quality development of the biomedicine industry; support may be provided on a case-by-case basis for important matters, key projects, and key enterprises.
related party

The policies involved in this website are widely collected from various public channels, except for indicating originality











